Impaired brain glucose metabolism in cirrhosis without overt hepatic encephalopathy

Abstract

Patients with cirrhosis have characteristic patterns of brain glycometabolic impairment. F-fluorodeoxyglucose PET/computed tomography may serve as a preclinical biomarker for brain damage in cirrhosis.